AVCN 467504
Alternative Names: AVCN-467504Latest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Avicanna
- Class Analgesics; Anti-inflammatories; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Musculoskeletal pain
Most Recent Events
- 27 Aug 2024 USPTO issued the patent covering topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain in USA
- 12 Aug 2024 Avicanna completes an observational trial in Musculoskeletal pain (Topical) and Inflammation (Topical) prior to August 2024
- 12 Aug 2024 Avicanna initiates an observational trial in Inflammation (Topical) prior to August 2024